sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Cardiac Biomarkers Market by Type (Myocardial muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA)), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis) and Location of Testing (Point of care, Laboratory)- Global Opportunity Analysis and Industry Forecast, 2014 - 2020

Cardiac Biomarkers Market by Type (Myocardial muscle Creatine Kinase (CK-MB),...

Home / Categories / Healthcare
Cardiac Biomarkers Market by Type (Myocardial muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA)), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis) and Location of Testing (Point of care, Laboratory)- Global Opportunity Analysis and Industry Forecast, 2014 - 2020
Cardiac Biomarkers Market by Type...
Report Code
RO1/113/1012

Publish Date
01/Aug/2015

Pages
103
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2350/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
CHAPTER 1 INTRODUCTION

1.1 Report description
1.2 Key Benefits
1.3 Key market segments
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXO perspective
2.2 Market beyond what to expect by 2025 ($Million)

2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario

CHAPTER 3 MARKET OVERVIEW

3.1 Market Definition and Scope
3.2 Biomarker diagnosis vs. conventional diagnosis
3.3 Assessment of key advantages and buying criteria for diagnostic biomarkers

3.3.1 Early diagnosis
3.3.2 Tissue specific diagnosis
3.3.3 Reduce clinical trials
3.3.4 Risk assessments
3.3.5 Consistent output

3.4 Key trends impacting the Cardiac biomarker market

3.4.1 Development of high sensitive biomarkers for risk stratification
3.4.2 Technological advancements in the cardiac biomarkers: Serum based biomarkers
3.4.3 Increasing demand for point of care cardiac diagnostics

3.5 Key Findings

3.5.1 Top Factors Impacting
3.5.2 Top Investment Pockets
3.5.3 Top winning strategies

3.6 Government Regulations and reimbursement
3.7 Reimbursement scenario
3.8 Porters five force Analysis

3.8.1 Bargaining power of suppliers
3.8.2 Bargaining power of buyers
3.8.3 Threats from substitute products
3.8.4 Threat from new entrants
3.8.5 Industry rivalry

3.9 Value chain analysis
3.10 Clinical Trials
3.11 Patent Analysis
3.12 Market Share Analysis, 2014
3.13 Market Dynamics

3.13.1 Drivers

3.13.1.1 Increasing prevalence of cardiovascular diseases
3.13.1.2 Cost effective
3.13.1.3 Non-invasive
3.13.1.4 Accuracy prediction
3.13.1.5 Assistant in clinical trials
3.13.1.6 Multi-marker application
3.13.1.7 Technological advancements using cardiac biomarkers combinations
3.13.1.8 Increasing point of care (POC) testing

3.13.2 Restraints

3.13.2.1 Government Regulation
3.13.2.2 Conformation in result
3.13.2.3 Complex process

3.13.3 Opportunities

3.13.3.1 Personalized medicine
3.13.3.2 Point of care (POCT) testing using cardiac biomarkers
3.13.3.3 Future DEVELOPMENTS IN novel cardiac biomarkers

CHAPTER 4 GLOBAL CARDIAC BIOMARKERS MARKET BY TYPE, 2014-2020

4.1.1 Introduction
4.1.2 Key market trends
4.1.3 Key growth factors and opportunities

4.1.3.1 Characteristics of cardiac biomarkers include:

4.1.4 Market size and forecast

4.2 Creatine Kinase (CK-MB)

4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast

4.3 Troponins(T,I)

4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast

4.4 Myoglobin

4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast

4.5 Natriuretic peptides (BNP and NT-proBNP)

4.5.1 Key market trends
4.5.2 Key growth factors and opportunities
4.5.3 Market size and forecast

4.6 Ischemia Modified Albumin

4.6.1 Key market trends
4.6.2 Key growth factors and opportunities
4.6.3 Market size and forecast

4.7 Others

4.7.1 Key market trends
4.7.2 Key growth factors and opportunities
4.7.3 Market size and forecast

CHAPTER 5 GLOBAL CARDIAC BIOMARKERS MARKET BY APPLICATION, 2014-2020

5.1 Myocardial Infarction

5.1.1 Market size and forecast

5.2 Congestive Heart Failure

5.2.1 Market size and forecast

5.3 Acute Coronary Syndrome

5.3.1 Market size and forecast

5.4 Atherosclerosis

5.4.1 Market size and forecast

5.5 Others

5.5.1 Market size and forecast

CHAPTER 6 GLOBAL CARDIAC BIOMARKERS MARKET BY LOCATION OF TESTING, 2014-2020

6.1 Point of care testing

6.1.1 Market size and forecast

6.2 Laboratory testing

6.2.1 Market size and forecast

CHAPTER 7 GLOBAL CARDIAC BIOMARKER MARKET BY GEOGRAPHY, 2014-2020

7.1 North America

7.1.1 Key market trends
7.1.2 Key growth factors and opportunities
7.1.3 Market size and forecast
7.1.4 United States
7.1.5 Canada
7.1.6 Mexico

7.2 Europe

7.2.1 Key market trends
7.2.2 Key growth factors and opportunities
7.2.3 Market size and forecast
7.2.4 United Kingdom
7.2.5 France
7.2.6 Germany
7.2.7 Others

7.3 Asia-Pacific

7.3.1 Key market trends
7.3.2 Key growth factors and opportunities
7.3.3 Market size and forecast
7.3.4 China
7.3.5 India
7.3.6 Australia
7.3.7 Japan
7.3.8 Rest of Asia Pacific Countries

7.4 LAMEA

7.4.1 Key market trends
7.4.2 Key growth factors and opportunities
7.4.3 Market size and forecast
7.4.4 Latin America
7.4.5 Middle East
7.4.6 Africa

CHAPTER 8 COMPANY PROFILES

8.1 Abbott laboratories

8.1.1 Company Overview
8.1.2 Company snapshot
8.1.3 Financial performance
8.1.4 Operating segment overview
8.1.5 Strategic moves and developments
8.1.6 SWOT analysis of Abbott Laboratories

8.2 Alere Inc.

8.2.1 Company overview
8.2.2 Alere Inc. snapshot
8.2.3 Operating business segments
8.2.4 Business performance
8.2.5 Key Strategies and developments
8.2.6 SWOT analysis of Alere Inc.

8.3 Siemens Healthcare

8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Financial performance
8.3.4 SWOT analysis of Siemens Healthcare

8.4 Roche Diagnostics Corporation

8.4.1 Company overview
8.4.2 Roche Diagnostics snapshot
8.4.3 Operating business segments
8.4.4 Financial performance
8.4.5 Strategic moves and developments
8.4.6 SWOT analysis Roche Diagnostics

8.5 Beckman Coulter

8.5.1 Company overview
8.5.2 Company Snapshot
8.5.3 Strategies and Development
8.5.4 Swot Analysis of Beckman Coulter, Inc.

8.6 Becton, Dickinson And Co.

8.6.1 Company overview
8.6.2 Becton Dickinson and Company snapshot
8.6.3 Operating Business Segments
8.6.4 Business performance
8.6.5 Key Strategies and development
8.6.6 SWOT analysis of Becton Dickinson and Company

8.7 Thermo Fisher Scientific

8.7.1 Company profile
8.7.2 Company snapshot
8.7.3 Business performance
8.7.4 Strategic moves and developments
8.7.5 SWOT analysis & strategic conclusions

8.8 BioMerieux

8.8.1 Company overview
8.8.2 BioMerieux snapshot
8.8.3 Business performance
8.8.4 Operating business segments
8.8.5 SWOT analysis of BioMerieux

8.9 Bio-Rad Laboratories

8.9.1 Company profile
8.9.2 Company snapshot
8.9.3 Business performance
8.9.4 Strategic moves and developments
8.9.5 SWOT analysis & strategic conclusions

8.10 Randox laboratories

8.10.1 Company overview
8.10.2 Randox Laboratories. snapshot
8.10.1 Strategic moves and developments
8.10.2 SWOT analysis of Randox Laboratories

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com